nach oben

Erschienen in:

06.11.2019 | Original Paper

Expression of vitamin D receptor, CYP27B1 and CYP24A1 hydroxylases and 1,25-dihydroxyvitamin D₃ levels in stone formers

verfasst von: Thalita Lima Melo, Priscila Ligeiro Gonçalves Esper, Lysien Ivania Zambrano, Milene Subtil Ormanji, Fernanda Guedes Rodrigues, Ita Pfeferman Heilberg

Erschienen in: Urolithiasis | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

The expression of vitamin D receptor (VDR) and 1,25-dihydroxyvitamin D₃ [1,25(OH)D] levels exceed the values of controls in some but not all hypercalciuric stone formers (HSF). We aimed to evaluate serum 1,25(OH)D levels, the expression of VDR, CYP27B1, and CYP24A1 hydroxylases in HSF in comparison with normocalciuric stone formers (NSF) and healthy subjects (HS). Blood samples, 24-h urine collections and a 3-day dietary record were obtained from 30 participants from each of the groups. The expression of VDR, CYP27B1, and CYP24A1 was measured by flow cytometry. HSF presented significantly higher urinary volume, sodium, magnesium, oxalate, uric acid, and phosphorus than NSF and HS. Calcium intake was lower in HSF versus NSF and HS (442 ± 41 vs 594 ± 42 and 559 ± 41 mg/day, respectively, p = 0.027). Ionized calcium was significantly lower in HSF than NSF (1.29 ± 0.0 vs 1.31 ± 0.0 mmol/L, p < 0.01). Serum 1,25(OH)D was significantly higher in HSF and NSF than HS (22.5 ± 1.2; 22.2 ± 1.2 vs 17.4 ± 1.2 pg/ml, p = 0.007) but serum 25(OH)D, PTH, klotho and plasma FGF-23 did not differ between groups. VDR expression was higher in HSF and NSF than HS (80.8 ± 3.2; 78.7 ± 3.3 vs 68.6 ± 3.2%, p = 0.023). Although CYP27B1 and CYP24A1 expressions were similar among all groups, the ratio of 1,25(OH)D/CYP24A1 was higher in HSF and NSF than in HS (1.43 ± 0.25 and 0.56 ± 0.10 vs 0.34 ± 0.06, p = 0.00). Stone formers, regardless of urinary calcium excretion, had higher VDR expression and 1,25(OH)D levels than HS, even in ranges considered normal. Higher 1,25(OH)D/CYP24A1 ratio suggested a lower degradation of 1,25(OH)D by CYP24A1 in HSF and NSF.

Coe FL, Worcester EM, Evan AP (2016) Idiopathic hypercalciuria and formation of calcium renal stones. Nat Rev Nephrol 12(9):519–533. https://doi.org/10.1038/nrneph.2016.101 CrossRefPubMedPubMedCentral

Moe OW (2005) Genetic hypercalciuria. J Am Soc Nephrol 16(3):729–745. https://doi.org/10.1681/ASN.2004100888 CrossRefPubMed

Heilberg IP, Goldfarb DS (2013) Optimum nutrition for kidney stone disease. Adv Chronic Kidney Dis 20(2):165–174. https://doi.org/10.1053/j.ackd.2012.12.001 CrossRefPubMed

Taylor EN, Hoofnagle AN, Curhan GC (2015) Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones. Clin J Am Soc Nephrol 10(4):667–675. https://doi.org/10.2215/CJN.07060714 CrossRefPubMedPubMedCentral

Sassi F, Tamone C, D’Amelio P (2018) Vitamin D: nutrient, hormone, and immunomodulator. Nutrients. https://doi.org/10.3390/nu10111656 CrossRefPubMedPubMedCentral

Frick KK, Asplin JR, Krieger NS, Culbertson CD, Asplin DM, Bushinsky DA (2013) 1,25(OH)₂D₃-enhanced hypercalciuria in genetic hypercalciuric stone-forming rats fed a low-calcium diet. Am J Physiol Ren Physiol 305(8):F1132–F1138. https://doi.org/10.1152/ajprenal.00296.2013 CrossRef

Favus MJ, Karnauskas AJ, Parks JH, Coe FL (2004) Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab 89(10):4937–4943. https://doi.org/10.1210/jc.2004-0412 CrossRefPubMed

Zerwekh JE, Yu XP, Breslau NA, Manolagas S, Pak CY (1993) Vitamin D receptor quantitation in human blood mononuclear cells in health and disease. Mol Cell Endocrinol 96(1–2):1–6CrossRef

Zerwekh JE, Reed BY, Heller HJ, González GB, Haussler MR, Pak CY (1998) Normal vitamin D receptor concentration and responsiveness to 1, 25-dihydroxyvitamin D3 in skin fibroblasts from patients with absorptive hypercalciuria. Miner Electrolyte Metab 24(5):307–313CrossRef

10.

Kaplan RA, Haussler MR, Deftos LJ, Bone H, Pak CY (1977) The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Investig 59(5):756–760. https://doi.org/10.1172/JCI108696 CrossRefPubMed

11.

Shen FH, Baylink DJ, Nielsen RL, Sherrard DJ, Ivey JL, Haussler MR (1977) Increased serum 1,25-dihydroxyvitamin D in idiopathic hypercalciuria. J Lab Clin Med 90(6):955–962PubMed

12.

Insogna KL, Broadus AE, Dreyer BE, Ellison AF, Gertner JM (1985) Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. J Clin Endocrinol Metab 61(3):490–495CrossRef

13.

Bataille P, Bouillon R, Fournier A, Renaud H, Gueris J, Idrissi A (1987) Increased plasma concentrations of total and free 1,25-(OH)2D3 in calcium stone formers with idiopathic hypercalciuria. Contrib Nephrol 58:137–142CrossRef

14.

Kim WT, Kim Y-J, Yun SJ, Shin K-S, Choi YD, Lee SC, Kim W-J (2014) Role of 1,25-dihydroxy vitamin D3 and parathyroid hormone in urinary calcium excretion in calcium stone formers. Yonsei Med J 55(5):1326–1332. https://doi.org/10.3349/ymj.2014.55.5.1326 CrossRefPubMedPubMedCentral

15.

Moyano MJ, Tejada MJGD, Lozano RG, Moruno R, Ortega R, Marti V, Sanchez Palencia R, Palma A, Perez Cano R (2007) Changes in bone mineral metabolism in patients with recurrent urolithiasis and vitamin D receptor gene polymorphisms. Preliminary results. Nefrologia 27(6):694–703PubMed

16.

Ketha H, Singh RJ, Grebe SK, Bergstralh EJ, Rule AD, Lieske JC, Kumar R (2015) Altered calcium and Vitamin D homeostasis in first-time calcium kidney stone-formers. PLoS One 10(9):e0137350. https://doi.org/10.1371/journal.pone.0137350 CrossRefPubMedPubMedCentral

17.

Giannini S, Nobile M, Castrignano R, Pati T, Tasca A, Villi G, Pellegrini F, D’Angelo A (1993) Possible link between vitamin D and hyperoxaluria in patients with renal stone disease. Clin Sci (London, England: 1979) 84(1):51–54CrossRef

18.

Heilberg IP, Martini LA, Szejnfeld VL, Carvalho AB, Draibe SA, Ajzen H, Ramos OL, Schor N (1994) Bone disease in calcium stone forming patients. Clin Nephrol 42(3):175–182PubMed

19.

Hess B, Ackermann M, Essig M, Takkinen R, Jaeger P (1995) Renal mass and serum calcitriol in male idiopathic calcium renal stone formers: role of protein intake. J Clin Endocrinol Metab 80(6):1916–1921. https://doi.org/10.1210/jcem.80.6.7775641 CrossRefPubMed

20.

Berlin T, Holmberg I, Bjorkhem I (1986) High circulating levels of 25-hydroxyvitamin D3 in renal stone formers with hyperabsorptive hypercalciuria. Scand J Clin Lab Investig 46(4):367–374. https://doi.org/10.3109/00365518609083684 CrossRef

21.

Hess B, Casez J-P, Takkinen R, Ackermann D, Jaeger P (1993) Relative hypoparathyroidism and calcitriol up-regulation in hypercalciuric calcium renal stone formers—impact of nutrition. Am J Nephrol 13:18–26CrossRef

22.

Vezzoli G, Caumo A, Baragetti I, Zerbi S, Bellinzoni P, Centemero A, Rubinacci A, Moro GL, Adamo D, Bianchi G, Soldati L (1999) Study of calcium metabolism in idiopathic hypercalciuria by strontium oral load test. Clin Chem 45(2):257–261CrossRef

23.

Misael da Silva AM, dos Reis LM, Pereira RC, Futata E, Branco-Martins CT, Noronha IL, Wajchemberg BL, Jorgetti V (2002) Bone involvement in idiopathic hypercalciuria. Clin Nephrol 57(3):183–191CrossRef

24.

Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD (2010) Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 21(2):353–361. https://doi.org/10.1681/ASN.2009040451 CrossRefPubMedPubMedCentral

25.

Worcester EM, Bergsland KJ, Gillen DL, Coe FL (2013) Evidence for increased renal tubule and parathyroid gland sensitivity to serum calcium in human idiopathic hypercalciuria. Am J Physiol Renal Physiol 305:F853–F860. https://doi.org/10.1152/ajprenal.00124.2013 CrossRefPubMedPubMedCentral

26.

Vezzoli G, Macrina L, Rubinacci A, Spotti D, Arcidiacono T (2016) Intestinal calcium absorption among hypercalciuric patients with or without calcium kidney stones. Clin J Am Soc Nephrol 11(8):1450–1455. https://doi.org/10.2215/CJN.10360915 CrossRefPubMedPubMedCentral

27.

Menon VB, Moyses RMA, Gomes SA, de Carvalho AB, Jorgetti V, Heilberg IP (2014) Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers. Clin J Am Soc Nephrol 9(7):1263–1270. https://doi.org/10.2215/CJN.10030913 CrossRefPubMedPubMedCentral

28.

Hu H, Zhang J, Lu Y, Zhang Z, Qin B, Gao H, Wang Y, Zhu J, Wang Q, Zhu Y, Xun Y, Wang S (2017) Association between circulating vitamin D level and urolithiasis: a systematic review and meta-analysis. Nutrients. https://doi.org/10.3390/nu9030301 CrossRefPubMedPubMedCentral

29.

Gray RW, Wilz DR, Caldas AE, Lemann J (1977) The importance of phosphate in regulating plasma 1,25-(OH)2-vitamin D levels in humans: studies in healthy subjects in calcium-stone formers and in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 45(2):299–306. https://doi.org/10.1210/jcem-45-2-299 CrossRefPubMed

30.

Caldas AE, Gray RW, Lemann J (1978) The simultaneous measurement of vitamin D metabolites in plasma: studies in healthy adults and in patients with calcium nephrolithiasis. J Lab Clin Med 91(5):840–849PubMed

31.

De Leenheer AP, Bauwens RM (1985) Radioimmunoassay for 1,25-dihydroxyvitamin D in serum or plasma. Clin Chem 31(1):142–146. https://doi.org/10.1016/0009-8981(85)90185-8 CrossRefPubMed

32.

Wong SY, Slater SR, Evans RA, Mason R, Lancaster EK, Acland SM, Eade Y, Hills E, Dunstan CR (1992) Metabolic studies in kidney stone disease. Q J Med 82(299):247–258PubMed

33.

Prié D, Ravery V, Boccon-Gibod L, Friedlander G (2001) Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney Int 60(1):272–276. https://doi.org/10.1046/j.1523-1755.2001.00796.x CrossRefPubMed

34.

Shakhssalim N, Gilani KR, Parvin M, Torbati PM, Kashi AH, Azadvari M, Golestan B, Basiri A (2011) An assessment of parathyroid hormone, calcitonin, 1,25 (OH)2 vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors. Urol Res 39(1):1–7. https://doi.org/10.1007/s00240-010-0276-3 CrossRefPubMed

35.

Sutton RAL, Walker VR (1986) Bone resorption and hypercalciuria in calcium stoneformers. Metabolism 35(6):485–488. https://doi.org/10.1016/0026-0495(86)90002-8 CrossRefPubMed

36.

Jarrar K, Amasheh RA, Graef V, Weidner W (1996) Relationship between 1,25 OH D, calcium and uric acid in urinary stone formers. Urol Int 56:16–20CrossRef

37.

Asplin JR, Bauer KA, Kinder J, Muller G, Coe BJ, Parks JH, Coe FL (2003) Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 63(2):662–669. https://doi.org/10.1046/j.1523-1755.2003.00763.x CrossRefPubMed

38.

Tang J, McFann KK, Chonchol MB (2012) Association between serum 25-hydroxyvitamin D and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–94. Nephrol Dial Transplant 27(12):4385–4389. https://doi.org/10.1093/ndt/gfs297 CrossRefPubMed

39.

Rendina D, Esposito T, Mossetti G, De Filippo G, Gianfrancesco F, Perfetti A, Magliocca S, Formisano P, Prie D, Strazzullo P (2012) A functional allelic variant of the FGF23 gene is associated with renal phosphate leak in calcium nephrolithiasis. J Clin Endocrinol Metab 97(5):E840–E844. https://doi.org/10.1210/jc.2011-1528 CrossRefPubMed

40.

Ferraro PM, Minucci A, Primiano A, De Paolis E, Gervasoni J, Persichilli S, Naticchia A, Capoluongo E, Gambaro G (2017) A novel CYP24A1 genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass. Urolithiasis 45(3):291–294. https://doi.org/10.1007/s00240-016-0923-4 CrossRefPubMed

41.

Nesterova G, Malicdan MC, Yasuda K, Sakaki T, Vilboux T, Ciccone C, Horst R, Huang Y, Golas G, Introne W, Huizing M, Adams D, Boerkoel CF, Collins MT, Gahl WA (2013) 1,25-(OH)(2)D-24 Hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis. Clin J Am Soc Nephrol 8(4):649–657. https://doi.org/10.2215/cjn.05360512 CrossRefPubMedPubMedCentral

42.

Mulay SR, Anders HJ (2016) Crystallopathies. N Engl J Med 375(13):e29. https://doi.org/10.1056/NEJMc1609332 CrossRefPubMed

43.

Ferraro PM, Mandel EI, Curhan GC, Gambaro G, Taylor EN (2016) Dietary protein and potassium, diet-dependent net acid load, and risk of incident kidney stones. Clin J Am Soc Nephrol 11(10):1834–1844. https://doi.org/10.2215/cjn.01520216 CrossRefPubMedPubMedCentral

44.

Vezzoli G, Dogliotti E, Terranegra A, Arcidiacono T, Macrina L, Tavecchia M, Pivari F, Mingione A, Brasacchio C, Nouvenne A, Meschi T, Cusi D, Spotti D, Montanari E, Soldati L (2015) Dietary style and acid load in an Italian population of calcium kidney stone formers. Nutr Metab Cardiovasc Dis 25(6):588–593. https://doi.org/10.1016/j.numecd.2015.03.005 CrossRefPubMed

45.

Trinchieri A, Lizzano R, Marchesotti F, Zanetti G (2006) Effect of potential renal acid load of foods on urinary citrate excretion in calcium renal stone formers. Urol Res 34(1):1–7. https://doi.org/10.1007/s00240-005-0001-9 CrossRefPubMed

46.

Martini LA, Cuppari L, Cunha MA, Schor N, Heilberg IP (1998) Potassium and sodium intake and excretion in calcium stone forming patients. J Ren Nutr 8(3):127–131CrossRef

47.

Moe OW, Preisig PA (2005) Hypothesizing on the evolutionary origins of salt-induced hypercalciuria. Curr Opin Nephrol Hypertens 14(4):368–372CrossRef

48.

Martini LA, Cuppari L, Colugnati FA, Sigulem DM, Szejnfeld VL, Schor N, Heilberg IP (2000) High sodium chloride intake is associated with low bone density in calcium stone-forming patients. Clin Nephrol 54(2):85–93PubMed

49.

Lieben L, Carmeliet G (2013) Vitamin D signaling in osteocytes: effects on bone and mineral homeostasis. Bone 54(2):237–243. https://doi.org/10.1016/j.bone.2012.10.007 CrossRefPubMed

50.

Vezzoli G, Baragetti I, Zerbi S, Caumo A, Soldati L, Bellinzoni P, Centemero A, Rubinacci A, Moro GL, Bianchi G (1998) Strontium absorption and excretion in normocalciuric subjects: relation to calcium metabolism. Clin Chem 44(3):586–590CrossRef

Titel: Expression of vitamin D receptor, CYP27B1 and CYP24A1 hydroxylases and 1,25-dihydroxyvitamin D3 levels in stone formers
verfasst von: Thalita Lima Melo
Priscila Ligeiro Gonçalves Esper
Lysien Ivania Zambrano
Milene Subtil Ormanji
Fernanda Guedes Rodrigues
Ita Pfeferman Heilberg
Publikationsdatum: 06.11.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Urolithiasis / Ausgabe 1/2020
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-019-01163-9

1H NMR-based metabolomic study of metabolic profiling for the urine of kidney stone patients

Original Paper

The usefulness of the maximum Hounsfield units (HU) in predicting the shockwave lithotripsy outcome for ureteral stones and the proposal of novel indicators using the maximum HU

Original Paper

Flexible ureterorenoscopy to treat upper urinary tract stones in children

Original Paper

Sex differences in the temperature dependence of kidney stone presentations: a population-based aggregated case-crossover study

Original Paper

Induction of enteric oxalate secretion by Oxalobacter formigenes in mice does not require the presence of either apical oxalate transport proteins Slc26A3 or Slc26A6

Original Paper

It is efficient to monitor the status of implanted ureteral stent using a mobile social networking service application

Original Paper

Neu im Fachgebiet Urologie

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

14.01.2025
Nierenkarzinom
Nachrichten

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Auf weichem Fahrradsattel ist nicht gut Kinder zeugen

14.01.2025
Erektile Dysfunktion
Nachrichten

Männer, die sich gern sportlich verausgaben, riskieren möglicherweise, fürs Vaterwerden nicht genug Kräfte übrig zu haben. In einer Studie fanden sich dafür zwar allenfalls schwache Anzeichen. Es gab jedoch eine Ausnahme.

Vorteile für Androgenentzug plus Androgenrezeptorblockade

14.01.2025
Prostatakarzinom
Nachrichten

Für Männer mit metastasiertem hormonsensitivem Prostata-Ca. (mHSPC), die keine Hormonchemotherapie wollen oder vertragen, ist der Androgenentzug plus Darolutamid eine Alternative: Das Progressionsrisiko wird im Vergleich zum alleinigen Androgenentzug fast halbiert.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Expression of vitamin D receptor, CYP27B1 and CYP24A1 hydroxylases and 1,25-dihydroxyvitamin D₃ levels in stone formers

Abstract

Weitere Artikel der Ausgabe 1/2020

1H NMR-based metabolomic study of metabolic profiling for the urine of kidney stone patients

The usefulness of the maximum Hounsfield units (HU) in predicting the shockwave lithotripsy outcome for ureteral stones and the proposal of novel indicators using the maximum HU

Flexible ureterorenoscopy to treat upper urinary tract stones in children

Sex differences in the temperature dependence of kidney stone presentations: a population-based aggregated case-crossover study

Induction of enteric oxalate secretion by Oxalobacter formigenes in mice does not require the presence of either apical oxalate transport proteins Slc26A3 or Slc26A6

It is efficient to monitor the status of implanted ureteral stent using a mobile social networking service application

Neu im Fachgebiet Urologie

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

Auf weichem Fahrradsattel ist nicht gut Kinder zeugen

Vorteile für Androgenentzug plus Androgenrezeptorblockade

Update Urologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten